EGFR-TKI靶向治疗联合放疗对晚期NSCLC脑转移患者的疗效及认知功能的影响

Download: PDF (462 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Received: 02 July 2026

PACS:

R739.41

Cite this article:

URL:

[1]	Liu Liang, Yang Qin, Lai Yong. Evaluation of the Regulatory Effect and Safety of Immune Checkpoint Inhibitors Combined with Interventional Therapy on Tumor Metabolic Activity in Elderly Patients with Advanced Non-small Cell Lung Cancer[J]. journal1, 2026, 46(5): 24-26.
[2]	. [J]. journal1, 2026, 46(3): 64-65.
[3]	Kang Lihua, Zhai Fengyu, Liu Yuefen. The Efficacy of Sintilimab Combined with Platinum-based Chemotherapy in the Treatment of Advanced NSCLC Patients and Its Influence on Serum Notch1 and Dickkopf-1 Levels[J]. journal1, 2026, 46(1): 20-24.
[4]	Zhang Rui, Jiang Qingfang, Feng Gaoqing, Zhang Minjie, Zhang Yuanhang. Clinical Comparison of 3D-ICBT and IC-ISBT for Locally Advanced Cervical Cancer[J]. journal1, 2026, 46(1): 42-44.
[5]	Zhang Yueliang, Gan Huizhen, Lin Hui'e, Huang Honghong. The Effect of Sintilimab Combined with GP Regimen Chemotherapy on Serum VEGF,BFGF Levels and Immune Indicators in Advanced NSCLC Patients[J]. journal1, 2025, 45(6): 18-20.
[6]	Li Lanju, Xu Ensong, Li Wenming, Zhang Nan. Effects of Pabolizumab on T Lymphocyte and Serum sMICA Levels in Patients with Non-small Cell Lung Cancer[J]. journal1, 2025, 45(4): 17-19.